唇癌近距离放疗(介入放疗):荷兰四中心经验显示优异局部控制、低毒性与高患者满意度
荷兰四家头颈癌近距离放疗中心回顾2009–2023年272例唇癌患者,83%为根治性、17%为辅助性近距离放疗,5年局部控制率97%,仅2.2%出现2级晚期毒性,80%患者非常满意。
要点
- 272例唇癌患者接受HDR或PDR近距离放疗,5年局部控制率97%。
- 所有患者出现急性黏膜炎但3个月内愈合,仅2.2%出现2级晚期毒性。
- 80%患者非常满意,辅助放疗者满意度≤7的比例高于根治性放疗者。
核心结论
- 近距离放疗(介入放疗)治疗唇癌可获得优异的局部控制、良好的毒性特征和高水平患者满意度,根治性与辅助性治疗均如此。
研究设计与样本
- 2009–2023年间荷兰四家近距离放疗专病头颈癌中心收治的272例唇癌患者,接受HDR或PDR近距离放疗,根治性占83%、辅助性占17%。
主要发现
- 中位随访36个月,全组5年实际局部控制率为97%,根治性与辅助性分别为96%与100%(p=159),HDR与PDR分别为98%与94%(p=671)。
- 全组最终局部和区域控制率分别达99.6%和98.9%。
- 所有患者发生急性黏膜炎并在3个月内愈合,4%患者延迟愈合,仅2.2%出现2级晚期毒性。
- 81例可评估满意度中,80%非常满意(评分9–10)、18%满意(评分7–8)、1例不满意;满意度评分≤7者占7.4%,其中25%接受辅助放疗、3%接受根治性放疗(p=0.002)。
关键数值与推荐
- 5年实际局部控制率全组97%,根治性96%、辅助性100%(p=159),HDR 98%、PDR 94%(p=671)。
- 2级晚期毒性发生率2.2%;满意度评分≤7者占7.4%,辅助放疗者该比例为25%、根治性者为3%(p=0.002)。
临床怎么用
- 唇癌近距离放疗可作为根治性或辅助性治疗选择,局部控制优异且晚期毒性低。
- 治疗前需告知患者急性黏膜炎普遍发生但多在3个月内愈合。
- 辅助性近距离放疗患者满意度评分偏低的比例较高,需加强支持与沟通。
局限性
- 满意度数据仅来自81例患者,非全队列可评估。
- 原文未报告前瞻性设计或对照分组,为多中心回顾性经验总结。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study is to evaluate oncologic outcomes, toxicity, and patient satisfaction after brachytherapy (interventional radiotherapy) for lip carcinoma at four brachytherapy-dedicated Dutch head-and-neck cancer centers. MATERIALS AND METHODS: Between 2009 and 2023, 272 patients with lip carcinoma were treated with high-dose-rate (HDR) or pulsed-dose-rate (PDR) brachytherapy, either primary (83%) or adjuvant (17%). The study endpoints were local and loco-regional control, acute and late toxicity, and patient satisfaction. RESULTS: In the entire cohort, 38 recurrences were reported in 31 patients (11.4%). These were nine local (3.3%), 22 regional (8.1%) and seven distant failures (2,6%). Most of these failures were successfully treated, resulting in ultimate local and regional control rates of 99.6 % and 98.9 %, respectively. After median follow-up of 36 months, the 5-years actuarial local control rate for the entire group was 97%. The rates for primary and adjuvant brachytherapy were 96% and 100% (p = 159) and for HDR and PDR were 98% and 94% (p = 671), respectively. All patients developed acute mucositis, which healed within three months. Delayed healing was observed in 4% of patients, and only 2.2% experienced grade 2 late toxicity. On three-points Likert scale for patients satisfaction (available from 81 patients), 80% was very satisfied (score 9-10), 18% satisfied (score 7-8) and only one patient was unsatisfied. Only 7.4% of patient had a satisfaction score of ≤ 7; 25% of them had received adjuvant, compared to 3% who received primary brachytherapy (p = 0.002). CONCLUSIONS: In the largest study to date, brachytherapy for lip carcinoma resulted in excellent local control, a favorable toxicity profile, and high level of patient satisfaction as well for those treated in the primary as in adjuvant settings.
引用
- Al-Mamgani A, Verduijn GM, Zwijnenburg E, et al. Brachytherapy (Interventional Radiotherapy) for lip carcinoma: excellent local control, low toxicity profile, and high patient satisfaction - The Dutch experience from four brachytherapy-dedicated head and neck cancer centers. Radiother Oncol. 2025. PMID: 41187793. doi:10.1016/j.radonc.2025.111243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。